Clinical trial for the effect of beta2 adrenargic receptor polymorphism to long acting beta agonist induced hypokalemia.

Clinical trial for the effect of beta2 adrenargic receptor polymorphism to long acting beta agonist induced hypokalemia. - The effect of beta2 adrenargic receptor polymorphism to long acting beta agonist induced hypokalemia.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005756

Enrollment

Registered

2011-06-13

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adult

Interventions

long acting beta agonist

Formoterol Formoterol/ Budesonide complex placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The cases with a genetic polymorphism that results in homozygosity for arginine (Arg/Arg), or glycine (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor. The cases with normal range of serum potassium levels.

Exclusion criteria

Exclusion criteria: Take any drugs. Hypertension; Systolic pressure >160mmHg or diastolic blood pressure >90mmHg or heart rate> 85 a minute Past history of hypertension, heart failure, atrial fibrillation, and extrasystole arrythmia. Abnormalities of ECG ; QTc>0.45s Pointed out of the hepatic or renal functional abnormality, and diabetes. Cigarette smoker. Postsurgery of the lung.

Design outcomes

Primary

Measure	Time frame
Serum potassium level after the Formoterol inhalation	—

Countries

Japan

Contacts

Public ContactIkkou Higashimoto

Kagoshima university Graduate school of medical and dental science Department of pulmonary medicine

ikkou@m2.kufm.kagoshima-u.ac.jp0992756481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026